COVID-19 vaccine immunology

COVID-19 vaccine immunological studies in Finland

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2021-004788-29-FI

Enrollment

4000

Registered

2021-09-17

Start date

2021-12-23

Completion date

Unknown

Last updated

2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 23.1 Level: LLT Classification code 10084464 Term: COVID-19 immunization System Organ Class: 100000004865

Interventions

Trade Name: Comirnaty Pharmaceutical Form: Concentrate for dispersion for injection INN or Proposed INN: Tozinameran (COVID-19 mRNA vaccine, nucleoside-modified) Other descriptive name: COVID-19 mRNA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 2500 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 1500

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Finland

Contacts

Public ContactNina Ekström

Finnish Institute for Health and Welfare

nina.ekstrom@thl.fi+35829524 8588

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026